{"id":2233,"date":"2024-09-30T00:00:00","date_gmt":"2025-03-17T01:28:11","guid":{"rendered":"https:\/\/www.rxbriefcase.com\/courses\/type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment\/"},"modified":"2025-11-05T11:33:06","modified_gmt":"2025-11-05T16:33:06","slug":"type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment","status":"publish","type":"eb_course","link":"https:\/\/www.rxbriefcase.com\/fr\/courses\/type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment\/","title":{"rendered":"Type 2 Diabetes and Pharmacotherapy: Should Metformin Remain the First-Line Treatment?"},"content":{"rendered":"<p dir=\"ltr\" style=\"text-align: left\">In this video, Dr. Ronald Goldenberg, an endocrinologist at LMC Diabetes and Endocrinology, discusses the evolving landscape of first-line therapy for type 2 diabetes. He reviews the historical role of metformin, the impact of landmark trials such as the UK Prospective Diabetes Study and explores the potential benefits of newer agents like SGLT2 inhibitors and GLP-1 receptor agonists, emphasizing individualized treatment approaches based on patient profiles and comorbidities.<\/p>","protected":false},"featured_media":28272,"comment_status":"closed","ping_status":"closed","template":"","eb_course_cat":[],"class_list":["post-2233","eb_course","type-eb_course","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Type 2 Diabetes and Pharmacotherapy: Should Metformin Remain the First-Line Treatment? - RxBriefCase<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rxbriefcase.com\/fr\/cours\/type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Type 2 Diabetes and Pharmacotherapy: Should Metformin Remain the First-Line Treatment? - RxBriefCase\" \/>\n<meta property=\"og:description\" content=\"In this video, Dr. Ronald Goldenberg, an endocrinologist at LMC Diabetes and Endocrinology, discusses the evolving landscape of first-line therapy for type 2 diabetes. He reviews the historical role of metformin, the impact of landmark trials such as the UK Prospective Diabetes Study and explores the potential benefits of newer agents like SGLT2 inhibitors and [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rxbriefcase.com\/fr\/cours\/type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"RxBriefCase\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-05T16:33:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2024\/09\/Diabetes-EB2_1916972390-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.rxbriefcase.com\/courses\/type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment\/\",\"url\":\"https:\/\/www.rxbriefcase.com\/courses\/type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment\/\",\"name\":\"Type 2 Diabetes and Pharmacotherapy: Should Metformin Remain the First-Line Treatment? - RxBriefCase\",\"isPartOf\":{\"@id\":\"https:\/\/www.rxbriefcase.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.rxbriefcase.com\/courses\/type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.rxbriefcase.com\/courses\/type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2024\/09\/Diabetes-EB2_1916972390-3.jpg\",\"datePublished\":\"2025-03-17T01:28:11+00:00\",\"dateModified\":\"2025-11-05T16:33:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.rxbriefcase.com\/courses\/type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.rxbriefcase.com\/courses\/type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.rxbriefcase.com\/courses\/type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment\/#primaryimage\",\"url\":\"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2024\/09\/Diabetes-EB2_1916972390-3.jpg\",\"contentUrl\":\"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2024\/09\/Diabetes-EB2_1916972390-3.jpg\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.rxbriefcase.com\/courses\/type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.rxbriefcase.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Course\",\"item\":\"https:\/\/www.rxbriefcase.com\/courses\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Type 2 Diabetes and Pharmacotherapy: Should Metformin Remain the First-Line Treatment?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.rxbriefcase.com\/#website\",\"url\":\"https:\/\/www.rxbriefcase.com\/\",\"name\":\"RxBriefCase\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.rxbriefcase.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.rxbriefcase.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.rxbriefcase.com\/#organization\",\"name\":\"RxBriefCase\",\"url\":\"https:\/\/www.rxbriefcase.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.rxbriefcase.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp\",\"contentUrl\":\"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp\",\"width\":190,\"height\":36,\"caption\":\"RxBriefCase\"},\"image\":{\"@id\":\"https:\/\/www.rxbriefcase.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Type 2 Diabetes and Pharmacotherapy: Should Metformin Remain the First-Line Treatment? - RxBriefCase","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rxbriefcase.com\/fr\/cours\/type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment\/","og_locale":"fr_CA","og_type":"article","og_title":"Type 2 Diabetes and Pharmacotherapy: Should Metformin Remain the First-Line Treatment? - RxBriefCase","og_description":"In this video, Dr. Ronald Goldenberg, an endocrinologist at LMC Diabetes and Endocrinology, discusses the evolving landscape of first-line therapy for type 2 diabetes. He reviews the historical role of metformin, the impact of landmark trials such as the UK Prospective Diabetes Study and explores the potential benefits of newer agents like SGLT2 inhibitors and [&hellip;]","og_url":"https:\/\/www.rxbriefcase.com\/fr\/cours\/type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment\/","og_site_name":"RxBriefCase","article_modified_time":"2025-11-05T16:33:06+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2024\/09\/Diabetes-EB2_1916972390-2.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.rxbriefcase.com\/courses\/type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment\/","url":"https:\/\/www.rxbriefcase.com\/courses\/type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment\/","name":"Type 2 Diabetes and Pharmacotherapy: Should Metformin Remain the First-Line Treatment? - RxBriefCase","isPartOf":{"@id":"https:\/\/www.rxbriefcase.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.rxbriefcase.com\/courses\/type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment\/#primaryimage"},"image":{"@id":"https:\/\/www.rxbriefcase.com\/courses\/type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2024\/09\/Diabetes-EB2_1916972390-3.jpg","datePublished":"2025-03-17T01:28:11+00:00","dateModified":"2025-11-05T16:33:06+00:00","breadcrumb":{"@id":"https:\/\/www.rxbriefcase.com\/courses\/type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rxbriefcase.com\/courses\/type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.rxbriefcase.com\/courses\/type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment\/#primaryimage","url":"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2024\/09\/Diabetes-EB2_1916972390-3.jpg","contentUrl":"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2024\/09\/Diabetes-EB2_1916972390-3.jpg","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/www.rxbriefcase.com\/courses\/type-2-diabetes-and-pharmacotherapy-should-metformin-remain-the-first-line-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.rxbriefcase.com\/"},{"@type":"ListItem","position":2,"name":"Course","item":"https:\/\/www.rxbriefcase.com\/courses\/"},{"@type":"ListItem","position":3,"name":"Type 2 Diabetes and Pharmacotherapy: Should Metformin Remain the First-Line Treatment?"}]},{"@type":"WebSite","@id":"https:\/\/www.rxbriefcase.com\/#website","url":"https:\/\/www.rxbriefcase.com\/","name":"Mallette Rx","description":"","publisher":{"@id":"https:\/\/www.rxbriefcase.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rxbriefcase.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.rxbriefcase.com\/#organization","name":"Mallette Rx","url":"https:\/\/www.rxbriefcase.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.rxbriefcase.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp","contentUrl":"https:\/\/www.rxbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp","width":190,"height":36,"caption":"RxBriefCase"},"image":{"@id":"https:\/\/www.rxbriefcase.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.rxbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course\/2233","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rxbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course"}],"about":[{"href":"https:\/\/www.rxbriefcase.com\/fr\/wp-json\/wp\/v2\/types\/eb_course"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rxbriefcase.com\/fr\/wp-json\/wp\/v2\/comments?post=2233"}],"version-history":[{"count":0,"href":"https:\/\/www.rxbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course\/2233\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.rxbriefcase.com\/fr\/wp-json\/wp\/v2\/media\/28272"}],"wp:attachment":[{"href":"https:\/\/www.rxbriefcase.com\/fr\/wp-json\/wp\/v2\/media?parent=2233"}],"wp:term":[{"taxonomy":"eb_course_cat","embeddable":true,"href":"https:\/\/www.rxbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course_cat?post=2233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}